II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease - Wikidata - awgldk - TriplyDB

II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease

II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease

http://www.wikidata.org/entity/Q29393271

about

S-adenosyl-L-methionine for alcoholic liver diseases Propylthiouracil for alcoholic liver disease Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases Anabolic-androgenic steroids for alcoholic liver disease Propylthiouracil for alcoholic liver disease S-adenosyl-L-methionine for alcoholic liver diseases Essential phospholipids in fatty liver: a scientific update The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?Vitamin-dependent methionine metabolism and alcoholic liver disease Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury Current status of novel antifibrotic therapies in patients with chronic liver disease Experience of a single center with congenital hepatic fibrosis: a review of the literature.Role of NADPH oxidases in liver fibrosis.Alcoholic liver disease: treatment Treatment of alcoholic liver disease.Aberrant hepatic methionine metabolism and gene methylation in the pathogenesis and treatment of alcoholic steatohepatitis.Antioxidants as therapeutic agents for liver disease.Review article: current management of alcoholic liver disease.Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia.KASL clinical practice guidelines: management of alcoholic liver disease Current and future anti-fibrotic therapies for chronic liver disease.Organizational Barriers to Adopting an Alcohol Screening and Brief Intervention in Community-Based Mental Health Organizations Pathophysiology and Management of Alcoholic Liver Disease: Update 2016.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies Pharmacotherapy of alcoholic liver disease in clinical practice.Harm reduction-a systematic review on effects of alcohol reduction on physical and mental symptoms.Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.Comparison of different bile acid-phospholipid conjugates in acute hepatitis.Halt and Reversal of Fibrosis.Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams.Antioxidants in the treatment of chronic liver diseases: why is the efficacy evidence so weak in humans?Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.From alcohol toxicity to treatment.Addressing liver fibrosis with liposomes targeted to hepatic stellate cells.Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.Essential phospholipids prevent islet damage induced by proinflammatory cytokines and hypoxic conditions.

P2860

Q24188041-B310A85B-F367-4350-ADC9-CE1E855DB0EA Q24236315-8EFD110E-0230-48F3-833A-C8BE4A85781B Q24243006-04A4BF70-0DB4-4F80-9657-AA6658354C92 Q24244334-F56CB720-F385-46BF-ADCD-A12B0139E093 Q24245565-B7EEEC98-02F4-4806-B011-F68E4A6784C8 Q24246175-8B83018E-2A9A-471E-B5C5-827D22C36744 Q26746216-BD0A2403-9320-4872-A37B-AC6405B2DA14 Q26766479-E841265D-A8F3-4B09-80E4-D5FF598429FE Q26769622-C5AE0059-FA06-4AAC-8134-6A8525650BF1 Q26996316-890A6D4B-5AD5-4D03-AF14-3890FE438B1F Q28242949-87F0FACF-5A68-4C51-9174-2CDA3BB34D8A Q28396783-40D29271-9969-4947-AB90-7E5823D652D6 Q30473375-C4B163C4-6173-4CCA-A159-C090CC60C957 Q33632334-65A711B8-4897-48A7-9710-0104CB020CEE Q33632736-3F3843F0-2A13-4C18-A6FB-3B9D47BD30C5 Q34255479-64F91229-30FC-4805-B6FA-C8F886AEE4B2 Q34565692-828B7B3E-FE89-4FCD-9E0D-101A00B3A120 Q35201613-B6C6B0F3-2621-4BB9-8C38-B988B565975F Q35585469-78E79091-3B7C-40CC-8ED0-8CDBD509B4A3 Q35714125-8DB63730-CE78-4A55-AE1D-14922C5B2402 Q37009615-F699302A-4CE4-4E16-978E-62D4A9023073 Q37229858-692EE10D-1F70-4210-870D-CCD1B0CE1929 Q37317654-737D9E59-E7B0-4842-857A-9653EDA681D9 Q37635923-4EE87A97-D42E-49C1-8559-889CAA39B421 Q37696026-9773A2E4-BFF2-479A-91BA-30DF95D8B46A Q38073028-7026CB40-4CEF-4AD4-9B06-76E78CA25316 Q38681092-E6A639B1-EF09-466E-8E37-8EC8A0B4C126 Q38879893-06D7A26B-D1C1-4F87-BBDC-82C48A3159DA Q39041281-F025F477-1DDC-4195-BDCA-E1DCAB1070BE Q39517348-148247BA-F9F3-4257-94C4-109D06A9D2A5 Q41762348-B514AEF4-F16D-4013-B31F-3DAE032F6BB7 Q42999771-11290935-00A7-4B8D-B2D0-EB42FFC66529 Q44666725-744A5385-BFCA-4DCD-A227-5293FC98EF84 Q45268831-D5BC9580-D2E4-491F-A0E4-65F50557A550 Q45983094-4E19F408-D3B8-47EE-8341-D9BE66857B8E Q46636339-E4726EB2-F065-4D75-8FCC-4434E30D59DA Q46641860-63C537BE-6CF8-4571-9B08-3A086EBEEEE0 Q46890423-772C12C9-03D2-4F3F-B168-34EA245A883D Q50356537-09A5913A-5E2B-4B46-90F0-4EE37216EA2B Q53342094-FC750516-72A8-4E52-A4F9-F94B56A5CBD4

P2860

II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease

http://www.wikidata.org/entity/Q29393271

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@ast

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@en

type

label

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@ast

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@en

prefLabel

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@ast

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@en

P1433

Q29393271-04FEE282-5267-42AB-A3A0-9BC74A787A2D

P1476

Q29393271-F0A22BED-1D3B-4BB6-900F-1F2A018059AC

P2093

Q29393271-25FCE89D-70E0-4B73-AC9F-5130DD01C3FA

Q29393271-2BDE8B23-1B23-4A0E-8D45-8C87EE40CB18

Q29393271-60AE6F93-4B47-42CF-8F41-6DA468001EA3

Q29393271-7EFD56FE-584F-4260-97B5-EE437D8E22E9

Q29393271-8F210B84-54BC-403E-BF3F-1F2BDCEA6AA6

P2860

Q29393271-03B7A851-CED7-4583-B515-D66F6938A54A

Q29393271-1787CC76-6F40-4889-9971-3203B25A3770

Q29393271-2AF2F913-EDEF-406B-8649-97D7BEE22EC8

Q29393271-56DFA42F-AF19-4A79-BC4C-AA654E82A745

Q29393271-5A6B0FA2-0973-404C-9140-98D996D76B96

Q29393271-8497F7AE-8610-4FE2-B679-861BF5F4842D

Q29393271-BDFC211C-C047-4E77-B295-FFF24283F4CB

Q29393271-BF155C60-56FF-48F3-9336-41E534F3E245

Q29393271-D2D4B2CF-1D45-482E-834B-BBAE8A98761C

Q29393271-E6D1A3D6-AF77-48B4-8AE9-E26A3E0A44B6

P304

Q29393271-FEDBEB95-BF26-4AC0-A850-29D8951FB571

P31

Q29393271-B0E1B33F-A167-4A92-94C0-167E9D4A42F8

P3181

Q29393271-9B1B58C0-C47A-457E-B863-B88CDB83DE18

P356

Q29393271-CF6BADCF-A823-40E4-92E1-749E4AE2EF9E

P433

Q29393271-5DC16E9F-CF00-456D-A2A3-1812B8AFD5D7

P478

Q29393271-340F1FB8-6A15-420B-A3CC-B58D4D95FC06

P577

Q29393271-654C0B2C-6022-4BEC-9E97-395C62F2A4D2

P698

Q29393271-07290B54-808D-4DE6-8FFA-A289E440F9CB

P921

Q29393271-F5565405-91C8-4FC0-A0BA-9036EE8F0B7F

P3181

P356

01.ALC.0000093743.03049.80

P1433

Alcoholism: Clinical and Experimental Research

P1476

II. Veterans Affairs Cooperati ...... ine in Alcoholic Liver Disease

@en

P2093

Charles S. Lieber

http://www.w3.org/2001/XMLSchema#string

David G. Weiss

http://www.w3.org/2001/XMLSchema#string

Fiorenzo Paronetto

http://www.w3.org/2001/XMLSchema#string

Roberto Groszmann

http://www.w3.org/2001/XMLSchema#string

Steven Schenker

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

Prior alcohol consumption and mortality following acute myocardial infarction.

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans.

Moderate alcohol consumption and risk of heart failure among older persons.

Should patients with heart disease drink alcohol?

I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams.

Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression.

A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies.

Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers.

P304

1765-1772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1823960

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/01.ALC.0000093743.03049.80

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14634492

http://www.w3.org/2001/XMLSchema#string

P921